CAR T-Cell Therapy

Lori A. Leslie, MD, discusses the impact that brexucabtagene autoleucel had on the treatment landscape for patients with relapsed or refractory mantle cell lymphoma.

Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.

Findings from an analysis of the KarMMa study in patients with multiple myeloma signal that certain baseline characteristics are predictive of response to chimeric antigen receptor T-cell therapy.

Results from the phase 2 CARITUDE-2 trial of ciltacabtagene autoleucel in patients with multiple myeloma signaled that a 1 infusion can achieve deep responses.

Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.

In patients with relapsed/refractory large B-cell lymphoma, the chimeric antigen receptor T-cell agent, lisocabtagene maraleucel demonstrated durable responses.

Robert J. Soiffer, MD, discusses how the role of transplantation is evolving with the availability of chimeric antigen receptor T-cell agents.

Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.

Chimeric antigen receptor T-cell therapy showed early efficacy and a tolerable safety profile with or without an mRNA vaccine in a phase 1 clinical trial.

CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.

Preclinical research indicates that anti-mesothelin chimeric antigen receptor T cells may be more effective than gavocabtagene autoleucel in mesothelin-expressing tumors.

Prolonged periods of radiographic and clinical improvement in children and young adults with H3K27M diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas has been shown with GD2-directed chimeric antigen receptor T cells.

In pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia who had a non-response to blinatumomab and a high-disease burden, worse outcomes were observed , according to retrospective research.

A phase 1 trial which will evaluate the safety and efficacy of chimeric antigen receptor T-cell therapy in ovarian cancer has begun.

Steve M. Albelda, MD, discusses the successes and downfalls of chimeric antigen receptor T cells in solid tumor research.

The FDA has granted approval to axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, according to an announcement from the FDA.

Treatment with AUTO1, an investigational CD19-targeted chimeric antigen receptor T-cell therapy, is being evaluated in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Chimeric antigen receptor expansion by day 10 could be an early biomarker to predict response and survival in patients with B-cell lymphoma.

Chimeric antigen receptor T cells manufactured using the Sleeping Beauty transposon in donor-derived cells and differentiated toward the cytokine-induced killer cell protocol induce a sustained response with minimal toxicities in patients with B-cell acute lymphoblastic leukemia.

Lisocabtagene maraleucel has demonstrated benefit to event-free survival for patients with relapsed/refractory large B-cell lymphoma.

The FDA has released a draft of new recommendations for the manufacture, development, and study design of chimeric antigen receptor T cells.

In an interview with Targeted Oncology, Steven M. Albelda, MD, discussed the introduction of chimeric antigen receptor T cells in solid tumor research and how it differs from what has been observed in hematologic malignancies.

Nitin Jain, MD, discusses the significance of a study of UCART22, an allogeneic chimeric antigen receptor T-cell therapy for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Jesus Berdeja, MD, discusses the safety profile observed with the newly approved chimeric antigen receptor T-cell therapy, ciltacabtagene autoleucel as observed in the phase 1/2 CARTITUDE-1 clincial trial.

In an interview with Targeted Oncology, Tanya Dorff, MD, discussed the exploration of chimeric antigen receptor T-cell therapy in prostate cancer, including recent findings from a phase 1 clinical trial.